SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurogen (NRGN)
An SI Board Since June 1996
Posts SubjectMarks Bans Symbol
523 35 0 NRGN
Emcee:  Terry McCormick Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
348I bought some today. Looks too cheap not to buy.Perhaps this is a more thinly trMadharry-6/20/2003
347VR1: The Journal of Pharmacology And Experimental Therapeutics Fast Forward FiMiljenko Zuanic-6/20/2003
346NRGN is having another active day, the past couple of weeks has had a few 250k phbolton-5/27/2003
345Proc Natl Acad Sci U S A 1982 Jun;79(11):3613-7 Specific recognition of the proscaram(o)uche-11/15/2002
344Nope, they pretty much go their own ways. Formation of the MAC is a classical tscaram(o)uche-11/15/2002
343Thanks WE. I am bit outdated (this is big BIT), so will need to do some readingMiljenko Zuanic-11/15/2002
342<i>Do you suggesting that c5aR antagonist may have different therapeutic ekeokalani'nui-11/15/2002
341Do you suggesting that c5aR antagonist may have different therapeutic effects thMiljenko Zuanic-11/14/2002
340Alexion's work has been largely I/R, focused on cardio and gut, and the c5 ckeokalani'nui-11/14/2002
339Is RA and asthma good target for C5a-R antagonist? ALXN data may share some lighMiljenko Zuanic-11/14/2002
338No questions during the q&a, I think for the 3rd straight quarterly call. rkrw-11/13/2002
337No update on CRF-R1 program. Did anyone listen CC?Miljenko Zuanic-11/12/2002
336Haven't looked at this in awhile, things seem to not be going well for NRGN,phbolton-11/12/2002
335Neurogen Corp Reports Alzheimer's Trial Results -2 Dow Jones, Tuesday, mopgcw-11/12/2002
334Neurogen Sees 4th Quarter Charge Up To $500,000 On Workforce Cuts Wednesday Octmopgcw-10/9/2002
333Neurogen Corporation Announces Staff Reduction Wednesday October 2, 8:07 pm ETmopgcw-10/3/2002
332Neurogen Corporation Announces Second Quarter 2002 Financial Results BRANFORD, mopgcw-8/8/2002
331Oppenheimer OppenheimerFunds acquired a 10.3 percent stake in drug discovery fimopgcw-7/11/2002
3303:15PM Neurogen falls on talk of Pfizer cancellation (NRGN) 8.52 -1.79: Stock slmopgcw-6/6/2002
329United States Patent 6,384,224 Greenlee , et al. May 7, 2002 Certain 1-(2-nJim Oravetz-5/30/2002
328Neurogen Corporation Announces First Quarter 2002 Financial Results Neurogen Cmopgcw-5/9/2002
327Neurogen Corporation Announces Its First Quarter 2002 Financial Results Conferenmopgcw-5/9/2002
326>>WASHINGTON -(Dow Jones)- Biotechnology Value Fund LP reported holding a tuck-4/5/2002
325Neurogen Corporation Announces Phase I Clinical Trial for Insomnia Drug BRANFORmopgcw-3/11/2002
324Neurogen Corporation Announces Fiscal Year 2001 Results BRANFORD, Conn., March mopgcw-3/5/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News